apilimod + atezolizumab

apilimod + atezolizumab is an investigational drug combination studied for cancer therapy, especially B-cell non-Hodgkin lymphoma. Apilimod is a small molecule inhibitor of **phosphatidylinositol-3-phosphate 5-kinase (PIKfyve)**, with additional anti-inflammatory properties due to inhibition of **interleukins IL-12 and IL-23**. Atezolizumab is a **monoclonal antibody targeting programmed death-ligand 1 (PD-L1)**, functioning as an immune checkpoint inhibitor that restores anti-tumor immunity. In preclinical models, **PIKfyve inhibition by apilimod can increase MHC class I expression and enhance the efficacy of immune checkpoint blockade (ICB)** such as atezolizumab, suggesting synergy between these two modalities[1][3][5]. The combination is primarily under development for relapsed or refractory B-cell non-Hodgkin’s lymphoma[1][3], with clinical trials ongoing[3].

Other names

STA-5326STA5326STA 5326